Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 183

1.

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, Levis M, Rudek M, Duffield A, Small D.

Blood. 2014 Mar 6;123(10):1525-34. doi: 10.1182/blood-2013-08-523035. Epub 2014 Jan 9.

PMID:
24408321
[PubMed - indexed for MEDLINE]
2.

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.

Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17.

PMID:
24046014
[PubMed - indexed for MEDLINE]
3.

Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.

Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Götze KS.

Cancer Res. 2011 Jul 1;71(13):4696-706. doi: 10.1158/0008-5472.CAN-10-4136. Epub 2011 May 5.

PMID:
21546568
[PubMed - indexed for MEDLINE]
Free Article
4.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
[PubMed - indexed for MEDLINE]
Free Article
5.

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 Mar 7;12:19. doi: 10.1186/1476-4598-12-19.

PMID:
23497317
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S.

Leukemia. 2012 Jul;26(7):1462-70. doi: 10.1038/leu.2012.52. Epub 2012 Feb 22.

PMID:
22354205
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia.

Ma HS, Nguyen B, Duffield AS, Li L, Galanis A, Williams AB, Brown PA, Levis MJ, Leahy DJ, Small D.

Cancer Res. 2014 Sep 15;74(18):5206-17. doi: 10.1158/0008-5472.CAN-14-1028. Epub 2014 Jul 24.

PMID:
25060518
[PubMed - in process]
8.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

PMID:
23969938
[PubMed - indexed for MEDLINE]
9.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.

J Hematol Oncol. 2013 Mar 16;6:21. doi: 10.1186/1756-8722-6-21.

PMID:
23497456
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.

Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D.

Blood. 2012 Oct 11;120(15):3069-79. doi: 10.1182/blood-2012-01-403493. Epub 2012 Aug 27.

PMID:
22927251
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.

Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, Spiekermann K, Bug G, Heinzel T, Böhmer FD, Krämer OH.

Mol Cancer Ther. 2012 Nov;11(11):2373-83. doi: 10.1158/1535-7163.MCT-12-0129. Epub 2012 Aug 31.

PMID:
22942377
[PubMed - indexed for MEDLINE]
Free Article
12.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D.

Blood. 2002 Jun 1;99(11):3885-91.

PMID:
12010785
[PubMed - indexed for MEDLINE]
Free Article
13.

Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.

Yoshida A, Ookura M, Zokumasu K, Ueda T.

Biochem Pharmacol. 2014 Jul 1;90(1):16-24. doi: 10.1016/j.bcp.2014.04.002. Epub 2014 Apr 13.

PMID:
24735609
[PubMed - indexed for MEDLINE]
14.

Targeting FLT3 for the treatment of leukemia.

Small D.

Semin Hematol. 2008 Jul;45(3 Suppl 2):S17-21. doi: 10.1053/j.seminhematol.2008.07.007. Review.

PMID:
18760705
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.

Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.

PMID:
12531805
[PubMed - indexed for MEDLINE]
Free Article
16.

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM.

Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.

PMID:
21482694
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144. Epub 2010 Feb 16.

PMID:
20159992
[PubMed - indexed for MEDLINE]
Free Article
18.

Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.

Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.

Br J Haematol. 2011 Oct;155(2):198-208. doi: 10.1111/j.1365-2141.2011.08819.x. Epub 2011 Aug 16.

PMID:
21848891
[PubMed - indexed for MEDLINE]
19.

BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.

Nordigården A, Kraft M, Eliasson P, Labi V, Lam EW, Villunger A, Jönsson JI.

Blood. 2009 Mar 5;113(10):2302-11. doi: 10.1182/blood-2008-07-167023. Epub 2008 Dec 8.

PMID:
19064725
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M.

J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.

PMID:
24002496
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk